Benefiting from optiDIFF: an interview with Nikolaos Nikolaou Learn about DefiniGEN's OptiDIFF platform and the advantages over current pre-clinical models for liver disease modeling
FDA modernization act The FDA Modernization Act 2.0's impact on pre-clinical approaches of rare monogenic liver and metabolic diseases
Revolutionizing Alpha-1-Antitrypsin Deficiency Therapeutics Learn more about the development of our exemplar A1ATD disease model
Webinar, Frequently Asked Questions Explore how iPSC-derived cells can be used to advance the efficiency and efficacy of disease modeling
